Pembrolizumab combined with axitinib in the treatment of skin metastasis of renal clear cell carcinoma to nasal ala: A case report
Shuai Dong, Yang-Chun Xu, Yuan-Chen Zhang, Jian-Xin Xia, Yan Mou, Department of Dermatology, The Second Hospital of Jilin University, Changchun 130041, Jilin Province, China
Author contributions: Dong S collected the data, did the literature searching and contributed to the manuscript drafting; Xu YC, Zhang YC and Xia JX did the follow-up and contributed to the manuscript drafting; Mou Y was the patient’s doctor, and revised and reviewed the manuscript; all authors gave final approval for the version to be submitted.
Supported by the National Natural Science Foundation of China, No. 81803160.
Informed consent statement: Informed consent was obtained from the patient for the publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist, and the manuscript was prepared and revised according to the CARE Checklist (2016).
: This article is an open-access article that was selected by an in-house editor and fully peer reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yan Mou, Doctor, MD, PhD, Associate Professor, Senior Consultant Dermatologist, Department of Dermatology, The Second Hospital of Jilin University, No. 218 Ziqiang Street, Changchun 130041, Jilin Province, China. email@example.com
Received: January 4, 2023
First decision: January 20, 2023
Revised: January 28, 2023
Accepted: February 27, 2023
Article in press: February 27, 2023
Published online: March 26, 2023